Figure 1.

Overall study design and frequency profiling for each cell type in scRNA-seq data. (A) Overview of this study integrating scRNA-seq of PBMCs, plasma proteome, and clinical information for healthy controls (HCs), patients with acetylcholine receptor-positive (AChR+) myasthenia gravis (MG), and seronegative (SN) MG pre-/post-intravenous immunoglobulin (IVIg)-treated patients. (B) Uniform Manifold Approximation and Projection (UMAP) showing 13 identified cell types: monocytes (CD14 positive monocytes), non-classical monocytes (CD16 positive monocytes), dendritic cells (DCs), plasmacytoid dendritic cells (pDCs), B cells, naïve CD4 T cells, CD4 T cells, regulatory T cells (Tregs), naïve CD8 T cells, CD8 T cells, natural killer (NK) cells, platelets, and unclassified cells in all samples (HCs, AChR+ MG, and SN MG pre-/post-IVIg treated patients). (C) Frequencies of each cell type for each sample. The frequency is presented as the percentage of each cell type when the total number of cells in each sample is 100%. Numbers beginning with H refer to healthy control, numbers beginning with A refer to patients with AChR+ myasthenia gravis, numbers beginning with N and ending with a refer to SN MG pre-intravenous immunoglobulin (IVIg)-treated patients, and numbers beginning with N and ending with b refer to SN MG post-intravenous immunoglobulin (IVIg)-treated patients. This number corresponds to the patient ID in Supplementary Table 3. (D) Boxplots of cell frequencies of cell types that showed significant differences in the Tukey’s HSD test (P < 0.05). Numerical values show the median for each group. Red lines and asterisks show significant combinations in the Tukey’s HSD test (*P < 0.05, **P < 0.005, and ***P < 0.0005).